FDA Approves FoundationOne CDx as a Companion Diagnostic for Lilly's Retevmo (selpercatinib) for Certain Patients with Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved FoundationOne CDx as a companion diagnostic for Eli Lilly's Retevmo (selpercatinib) for certain patients with solid tumors. This approval could potentially increase the usage of Retevmo, thereby boosting Eli Lilly's revenues.
October 09, 2023 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA approval of FoundationOne CDx as a companion diagnostic for Eli Lilly's Retevmo could potentially increase the usage of Retevmo, thereby boosting Eli Lilly's revenues.
The FDA approval of FoundationOne CDx as a companion diagnostic for Retevmo could lead to increased usage of the drug. This could potentially result in increased revenues for Eli Lilly, which would likely have a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100